Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated bifidobacterium breve 207-1
- Development stage
- Unknown
- Lead developer
- Life-Space
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Inactivated Bifidobacterium breve 207-1 is a postbiotic (inactivated microbial) preparation derived from a specific strain of *Bifidobacterium breve* originally isolated from the intestinal tract of healthy newborns in China. Developed by By-Health, the strain is deposited at the Guangdong Province Collection of Microorganisms under accession number GDMCC No. 60962. The inactivated form consists of heat-killed bacterial cells that retain biological activity, including the ability to stimulate macrophage immune responses and increase the secretion of the anti-inflammatory cytokine interleukin-10 (IL-10). Research indicates that it modulates the daf-2/daf-16 (insulin/FOXO) signaling pathway, which is involved in metabolic regulation and longevity. It is being investigated for a range of therapeutic applications, including inflammatory bowel diseases, allergic conditions (by reducing serum IgE levels), metabolic syndrome (glycolipid metabolic disorders, obesity, and fatty liver), and mental wellness conditions such as stress, insomnia, and fatigue via the microbiome-gut-brain axis.
- Other names
- 短双歧杆菌207-1灭活菌Bifidobacterium breve 207-1GDMCC No. 60962
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)IL10 (Interleukin-10)FOXO1 (Forkhead box protein O1)
Beyond the preview
Go deeper on inactivated bifidobacterium breve 207-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated bifidobacterium breve 207-1.